Sandoz Receives FDA Approval for Enzalutamide ANDA216068
Sandoz has received FDA approval for its Abbreviated New Drug Application (ANDA) for Enzalutamide.
Therapeutic Area
Therapeutic area intelligence for Androgen Receptor Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.